Note especially the bottom of page 69 where it talks about Occupational Exposures–encounters between vaccinated and non-vaccinated. These are references to potential shedding issues.
Sources:
- November 2020. “A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS.” PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) | Protocol C4591001. Pfizer-BioNTech.
https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdf.
Pfizer, PDF.
This is the vaccine study protocol produced by Pfizer. - August 30, 2021. “Item of Interest: NIH Funds Studies to Assess Potential Effects of COVID-19 Vaccination on Menstruation.” National Institute of Child Health and Human Development.
https://www.nichd.nih.gov/newsroom/news/083021-COVID-19-vaccination-menstruation.
National Institutes of Health. - September 8, 2021. Stew Peters with Jane Ruby. “Ask Dr. Jane: ‘Shedding’, Breastfeeding, Self-Spreading ‘Contagious’ Vaccines.” Red Voice Media, The Stew Peters Show.
https://www.redvoicemedia.com/2021/09/ask-dr-jane-shedding-breastfeeding-self-spreading-contagious-vaccines/.
News, Video.
Related:
- August 2015. “Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products – Guidance for Industry.” US Food & Drug Administration.
https://www.fda.gov/media/89036/download.
Food & Drug Administration, PDF. - August 25, 2021. BioNTech SE. “A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS.” Clinical trial registration NCT04368728. clinicaltrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04368728.
Research Journal.